BioArctic

BioArctic Days Payable Outstanding

The Days Payable Outstanding (DPO) of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 147.57. In the previous year, Days Payable Outstanding (DPO) was 682.45 — a change of -78.38% (lower).

Days Payable Outstanding

147.57

YoY

-78.38%

Last updated:

Days Payable Outstanding (DPO) of BioArctic is 2025 147.57 . Days Payable Outstanding (DPO) of BioArctic was 2024 682.45 . It decreases by -78.38% lower compared to the previous year.

The BioArctic Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
37.18 SEK
Jan 1, 2019
41.42 SEK
Jan 1, 2020
103.97 SEK
Jan 1, 2021
78.33 SEK
Jan 1, 2022
105.54 SEK
Jan 1, 2023
121.63 SEK
Jan 1, 2024
682.45 SEK
Jan 1, 2025
147.57 SEK
The BioArctic Days Payable Outstanding history
YEARDays Payable OutstandingYoY
147.57-78.38%
682.45+461.08%
121.63+15.25%
105.54+34.73%
78.33-24.66%
103.97+151.02%
41.42+11.39%
37.18-99.64%
10,409.36-42.17%
17,998.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Days Payable Outstanding (DPO) of BioArctic is 147.57 in 2025.

Days Payable Outstanding (DPO) of BioArctic changed from 682.45 to 147.57, representing a -78.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) BioArctic since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioArctic

All Key Metrics — BioArctic